PROPHYLAXIS WITH RIVAROXABAN AGAINST VENOUS THROMBOEMBOLISM (VTE): A COST-CONSEQUENCE ANALYSIS FROM THE PERSPECTIVE OF THE ITALIAN HEALTH CARE SERVICE

被引：2
|
作者：
Negrini, C. [1 ]
Diamantopoulos, A. [2 ]
Forster, F. [2 ]
Lopatriello, S. [3 ]
Lees, M. [4 ]
Bianchi, C. [5 ]
Pedone, M. P. [5 ]
机构：
[1] PBE Consulting, Milan, Italy
[2] IMS Hlth, London, England
[3] Pbe Consulting, Verona, Italy
[4] Bayer HealthCare, Uxbridge, Middx, England
[5] Bayer HealthCare, Milan, Italy
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)66764-2
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A534 / A534
页数：1
相关论文
共 50 条
  • [1] IMPACT ON ITALIAN NATIONAL HEALTH SERVICE EXPENDITURE FOR THE TREATMENT OF VENOUS THROMBOEMBOLISM WITH RIVAROXABAN
    Roggeri, A.
    Roggeri, D. P.
    Pengo, V
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A384 - A384
  • [2] A COST-CONSEQUENCE ANALYSIS OF DIFFERENT PROTEASE INHIBITORS SCHEMES FOR HIV TREATMENT FROM THE COLOMBIAN HEALTH CARE SYSTEM PERSPECTIVE
    Rueda, J. D.
    Ariza, J. G.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A713 - A713
  • [3] Cost-consequence analysis of long-term prophylaxis in the treatment of von Willebrand disease in the Italian context
    Schinco, Piercarla
    Cultrera, Dorina
    Valeri, Federica
    Borchiellini, Alessandra
    Mantuano, Michela
    Gorla, Francesca
    Savarese, Alessia
    Teruzzi, Cristina
    [J]. CLINICOECONOMICS AND OUTCOMES RESEARCH, 2015, 7 : 17 - 25
  • [4] Real-Life Management of Venous Thromboembolism With Rivaroxaban: Results From EXperience VTE, an Italian Epidemiological Survey
    Imberti, Davide
    Barillari, Giovanni
    [J]. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2018, 24 (02) : 241 - 247
  • [5] VTE PROPHYLAXIS IN CRITICAL CARE PATIENTS: DATA FROM VTE START (VENOUS THROMBOEMBOLISM STUDY TO ASSESS THE RATE OF THROMBOPROPHYLAXIS)
    Dobesh, Paul
    Amin, Alpesh
    Klepser, Donald
    [J]. CRITICAL CARE MEDICINE, 2010, 38 (12) : U5 - U5
  • [6] A comparison of aspirin against rivaroxaban for venous thromboembolism prophylaxis after hip or knee arthroplasty: A meta-analysis
    Xu, Joshua
    Kanagaratnam, Aran
    Cao, Jacob Y.
    Chaggar, Gurpreet S.
    Bruce, Warwick
    [J]. JOURNAL OF ORTHOPAEDIC SURGERY, 2020, 28 (01)
  • [7] A cost-consequence analysis of treatment of vesicoureteral reflux (VUR): Which children benefit from antimicrobial prophylaxis?
    Shaikh, N.
    Rajakumar, V.
    Gorski, J.
    Ivanova, A.
    Gravens-Muller, L.
    Pohl, H.
    Matthews, R.
    Hoberman, A.
    [J]. PEDIATRIC NEPHROLOGY, 2016, 31 (10) : 1759 - 1759
  • [8] Cost-consequence analysis of Pharmaceutical Care program for systemic arterial hypertension in the public health system in Brazil
    Cazarim, Maurilio de Souza
    Nunes, Altacilio Aparecido
    Leira Pereira, Leonardo Regis
    [J]. BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 53 (03)
  • [9] BUDGET IMPACT MODEL (BIM) OF RIVAROXABAN IN COMPARISON WITH ENOXAPARIN PLUS WARFARIN IN THE TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) UNDER THE PERSPECTIVE OF THE PRIVATE HEALTH SYSTEM
    Piedade, A.
    Paladini, L.
    Tobaruella, F.
    Nakada, C.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A383 - A384
  • [10] COST-MINIMIZATION ANA LYSIS OF RIVAROXABAN IN COMPARISON TO ENOXAPARIN PLUS WARFARIN FOR THE TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) UNDER THE PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
    Piedade, A.
    Paladini, L.
    Tobaruella, F.
    Nakada, C.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A394 - A394
12345